Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

This study has been completed.
Information provided by:
Inotek Pharmaceuticals Corporation Identifier:
First received: January 3, 2006
Last updated: November 27, 2006
Last verified: November 2006
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.

Condition Intervention Phase
Acute Myocardial Infarction
Drug: INO-1001
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Prevention
Official Title: A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Inotek Pharmaceuticals Corporation:

Primary Outcome Measures:
  • The safety of INO-1001 will be measured by evaluation of symptoms, vital signs, physical examination, laboratory data, electrocardiograms, etc.

Secondary Outcome Measures:
  • The effect of INO-1001 on heart muscle damage will be evaluated by blood tests. Other blood tests will measure how INO-1001 is absorbed and removed by the body after exposure to different doses.

Estimated Enrollment: 40
Study Start Date: January 2004
Estimated Study Completion Date: June 2006
Detailed Description:

Currently, heart attacks may be treated with clot-dissolving medicines, coronary angioplasty, or a combination of both. Unblocking of blood flow to the heart following coronary angioplasty can cause side effects such as heart tissue and blood vessel damage, abnormal heart rhythms and death of heart muscle cells.

In animal studies, the PARP enzyme has been shown to be involved in damaging heart muscle after the sudden unblocking of coronary arteries. INO-1001 blocks the PARP enzyme, and so it may reduce heart damage in humans who have had their coronary arteries unblocked after a heart attack.

A total of 40 patients will be selected and randomly assigned to either INO-1001 or placebo (sugar water). One dose only of the drug will be given prior to coronary angioplasty. Patients will be followed until 30 days after surgery.

The following information will be gathered: vital signs, symptoms, physical examination, blood and urine tests, electrocardiograms, and other information from medical charts.

The information provided in this listing is disclosed solely to comply with regulatory requirements. The drug INO-1001 has not yet been approved for marketing and is only available to patients who participate in a clinical trial and are chosen for the treatment group.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with acute myocardial infarction (as defined in protocol) with onset within 24 hours prior to randomization.
  • Scheduled for primary percutaneous coronary intervention within 3 hours of presentation at a hospital participating in this study.
  • Males and non-pregnant, non-lactating females.

Exclusion Criteria:

  • Subjects will be required to undergo a full medical review in order to exclude serious medical, or psychological illness prior to inclusion.
  • History of a hypersensitivity reaction to more than three drugs or mannitol.
  • Participation in any investigational study within 30 days of randomization
  • Treatment with certain restricted medications within a specified time prior to participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00271765

United States, Florida
Holy Cross Hospital
Fort Lauderdale, Florida, United States, 33308
United States, Indiana
Porter Hospital
Valparaiso, Indiana, United States, 46383
United States, Minnesota
St. Paul Heart Clinic
St. Paul, Minnesota, United States, 55102
United States, New Jersey
Newark, New Jersey, United States
United States, Ohio
Toledo Hospital
Toledo, Ohio, United States, 43606
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
United States, South Dakota
Black Hills Cardiovascular Research
Rapid City, South Dakota, United States, 57701
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Sentara Norfolk General Hospital
Norfolk, Virginia, United States
United States, West Virginia
West Virginia University
Morgantown, West Virginia, United States, 26506
Rambam Medical Center
Haifa, Israel, 31096
Meir Medical Center
Kfar Saba, Israel, 95847
Hasharon Medical Center
Petach Tikva, Israel, 49100
Rabin Medical Center
Petach Tikva, Israel, 49100
Rehovot, Israel
Assaf Harofe Medical Centre
Zerifin, Israel
Sponsors and Collaborators
Inotek Pharmaceuticals Corporation
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00271765     History of Changes
Other Study ID Numbers: IPC-15-2003
Study First Received: January 3, 2006
Last Updated: November 27, 2006

Keywords provided by Inotek Pharmaceuticals Corporation:
Myocardial infarction
Coronary angioplasty
PARP inhibitor
PARP inhibition
Heart Attack

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on April 21, 2017